Abstract:Abstract Background In the ATN ( A myloid b, T au, N eurodegeneration) biomarker research framework proposed for Alzheimer’s Disease (AD), a critical need is the identification of robust markers of neurodegeneration (“N”) for more accurate disease state diagnosis and prognosis. Targeted proteomic profiling can be highly valuable for identifying such markers. Method We reanalyzed OlinkTM data from 270 CSF and plasma samples from the Swedish BioFINDER study (Whelan et al. 2019) using additional normalization and adjustments to reduce technical variation and inter‐subject heterogeneity. These include 1) plate‐level quantile normalization, 2) adjustment for age, gender, BMI, and anti‐inflammatory drugs, and 3) first principal component as a covariate to account for heterogeneity in control subjects from different cohorts. Our analysis cohort included 140 Aβ+ cognitively normal (ApCN), 65 Aβ+ mild cognitive impairment (ApMCI), and 138 Aβ + AD (ApAD) subjects. Proteins with false discovery rate < 5% and Cohen’s D ≥ 0.5 were considered statistically significant. Multiscale Embedded Gene Co‐expression Network Analysis (MEGENA) was used to identify co‐expressing network modules and hub proteins. Result Our analysis identified significant alterations of 65 CSF and 94 plasma proteins comparing different pairs of ApAD, ApMCI and ApCN groups. AUC ranged from 61% to 86% for differentiating ApAD vs ApCN. MMP‐10 was found to be significantly altered in all CSF comparisons, but not in plasma. We identified many significantly altered proteins not reported by Whelan et al (2019), including TFF3, EFNA4, and CTSC that are known to be associated with neurodegeneration or neuroinflammation. MEGENA analysis identified 10 network modules for CSF and 17 network modules for plasma. The most significant CSF modules were represented by IGFB‐2 and PLC hub proteins and enriched for positive regulation of cellular function. The most significant plasma modules were represented by SIRT2 and LAT and enriched for cellular response to stimulus. Conclusion Targeted proteomic profiling of matching CSF and plasma samples along with co‐expression network analysis can yield additional markers in the ATN framework for early detection and screening for AD.

Defining Alzheimer's Disease through Proteomic CSF Profiling

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Serum Metabolites Differentiate Amnestic Mild Cognitive Impairment From Healthy Controls And Predict Early Alzheimer'S Disease Via Untargeted Lipidomics Analysis

Characterization of proteome of human cerebrospinal fluid.

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Alzheimer disease pathology and the cerebrospinal fluid proteome

Proteomics analysis of prefrontal cortex of Alzheimer's disease patients revealed dysregulated proteins in the disease and novel proteins associated with amyloid-β pathology

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease

Potential Prognostic Value of CSF-targeted Proteomics Across the Alzheimer’s Disease Continuum

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease

CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease

Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer's disease biomarkers

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease

Profiling Human Cerebrospinal Fluid (CSF) Endogenous Peptidome in Alzheimer's Disease

Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics

Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates

Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies

Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment